Fusion proteins consisting of Bet v 1 and Phl p 5 form IgE-reactive aggregates with reduced allergenic activity
Open Access
- 8 March 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-12
Abstract
The cross-linking of effector cell-bound IgE antibodies by allergens induces the release of inflammatory mediators which are responsible for the symptoms of allergy. We demonstrate that a recombinant hybrid molecule consisting of the major birch (Bet v 1) and grass (Phl p 5) pollen allergen exhibited reduced allergenic activity as compared to equimolar mixes of the isolated allergens in basophil activation experiments. The reduced allergenic activity of the hybrid was not due to reduced IgE reactivity as demonstrated by IgE binding experiments using sera from allergic patients. Physicochemical characterization of the hybrid by size exclusion chromatography, dynamic light scattering, negative-stain electron microscopy and circular dichroism showed that the hybrid occurred as folded aggregate whereas the isolated allergens were folded monomeric proteins. IgG antibodies raised in rabbits against epitopes of Bet v 1 and Phl p 5 showed reduced reactivity with the hybrid compared to the monomeric allergens. Our results thus demonstrate that aggregation can induce changes in the conformation of allergens and lead to the reduction of allergenic activity. This is a new mechanism for reducing the allergenic activity of allergens which may be important for modifying allergens to exhibit reduced side effects when used for allergen-specific immunotherapy.Keywords
Funding Information
- Austrian Science Fund (F4607, P23318, F4604, F4605, F4611, F4611, F4613, F4604, F4611, F4613, F4605, F4607, P23318)
This publication has 51 references indexed in Scilit:
- Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimerMolecular Immunology, 2011
- Recombinant monoclonal human immunoglobulin E to investigate the allergenic activity of major grass pollen allergen Phl p 5Clinical & Experimental Allergy, 2010
- A convenient and sensitive allergy test: IgE crosslinking‐induced luciferase expression in cultured mast cellsAllergy, 2010
- Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivativesClinical & Experimental Allergy, 2008
- Differential regulation of mast cell cytokines by both dexamethasone and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580Clinical and Experimental Immunology, 2004
- Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicityThe FASEB Journal, 2002
- Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapyEuropean Journal of Immunology, 2002
- Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1The FASEB Journal, 2001
- Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1Journal of Allergy and Clinical Immunology, 1997
- Induction of specific histamine release from basophils with purified natural and recombinant birch pollen allergensJournal of Allergy and Clinical Immunology, 1993